Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 26   

Articles published

APPY 1.41 +0.06 (4.44%)
price chart
Venaxis, Inc. (APPY) Presents APPY1 Test Data at ACEP14
Venaxis, Inc. (NASDAQ: APPY) announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ...  MarketWatch
Related articles »  
Venaxis: Latest Clinical Data Reveals Huge Market Potential (APPY)
Venaxis Inc. recently reported detailed data of the clinical pathways undertaken by the pediatric patients enrolled in their pivotal trial.
Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14
CASTLE ROCK, Colo., Oct. 14, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, ...
Related articles »  
Pre-Open Stock Movers 10/28: (RCPT) (TRNX) (VDSI) (MSG) Higher; (TWTR ...
Venaxis, Inc. (NASDAQ: APPY) 9% HIGHER; announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Related articles »  
After-Hours Stock Movers 10/27: (TRNX) (RCPT) (SANM) Higher; (AKMR ...
Venaxis, Inc. (NASDAQ: APPY) 9% HIGHER; announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Related articles »  
Top Stocks: Top Stocks Gainers NASDAQ After Hours � SANM, GIGA, APPY ...
Venaxis Inc. (NASDAQ: APPY) traded at $1.45 up 7.4 percent during After Hours sessions on 3700 total share volume. APPY traded -13.83 percent below its fifty-day moving average and -35.83 percent below its 200-day moving average.
Watch List: MetLife (NYSE:MET), Twitter Inc (NYSE:TWTR), DSP Group Inc ...
Venaxis, Inc. (NASDAQ:APPY) announced that results of the company's pivotal APPY1 clinical trial will be presented on 27 October by Dr.
Appeals court tosses fraud claim against Colorado medical-device firm
In 2010, after tests of AppyScore yielded poor results, the company's stock tanked and new executives were hired. Later, the company revamped the device, calling it Appy1, and changed the company name to Venaxis Inc. (Nasdaq: APPY).
Court dismisses claim that AspenBio Pharma CEO intended to defraud
A lawsuit against Castle Rock-based AspenBio Pharma Inc. and current and former executives has been dismissed by the 10th U.S.
Investors Alert: JinkoSolar Holding Co., Ltd. (NYSE:JKS), ARM Holdings plc ...
Venaxis, Inc. (NASDAQ:APPY) announced that results of the company's pivotal APPY1 clinical trial will be presented on 27 October by Dr.
Related articles »